Jay Lee, MD, talks about financial toxicity in terms of the individual patient and in terms of the health system itself, especially in terms of non-small cell lung cancer (NSCLC) recurrence.
Jay Lee, MD, thoracic surgeon, surgical director, thoracic oncology program, University of California Los Angeles Health, division of thoracic surgery, and presenter at the CHEST Annual Meeting 2023 discusses the cost of financial toxicity in patients with non-small cell lung cancer (NSCLC) who experienced a recurrence and those who didn’t.
Transcript
What role does financial toxicity play in in the treatment of NSCLC?
Financial toxicity can be looked at in 2 ways. One is at the personal patient level and what kind of financial responsibilities are they faced with? And then also, financial toxicity in the reimbursement at the insurance claims level where health care resource utilization can be seen system wide. It's hard to collect data on the patient portion and what their financial responsibilities are.
However, we did look at the Sears Medicare database and looked at claims and associated costs of patients in the early stage [NSCLC] setting that have surgery. When patients develop recurrences versus no recurrences, inherently, we expect that cost will be higher when a patient develops a recurrence, but there hasn't been a whole lot of data about what those numbers actually are.
We reported on real world data analysis from the Medicare Sears database, and what we found was that when you look at health care resources, including inpatient visits, outpatient visits, physician services and emergency department visits, all of those resources were higher in patients that had recurrences. When we define a health care unit as per patient per month health care resource utilization—we defined this as PPPM in our in our reports that we have published on—what we find is that the average per patient per month cost when a patient develops a recurrence is roughly about $7,400. Compared to a patient that doesn't develop recurrence, it's about $1,100 per patient per month.
So, there's a significant difference in in the financial toxicity to the health system overall, in patients that develop a recurrence. This really points to the importance of preventing recurrences, not only because it's important as a surrogate for overall survival, but it's also beneficial from a financial perspective to reduce recurrences to the health care system.
AUA Posters Highlight Racial Gaps in PSA Screening, Prostate Cancer Risk
May 4th 2024Speakers discussed the disparities in prostate-specific antigen (PSA) screening rates among different racial groups and explored the potential of free PSA percentage as a predictive marker for future prostate cancer risk.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More